Vascular Contributions to Mechanisms and Biomarkers of Alzheimer’s Disease
-
- STATUS
- Recruiting
-
- End date
- Jul 31, 2025
Updated on 9 September 2022
cognitive impairment
cognitive decline
mild cognitive impairment
Accepts healthy volunteers
Summary
This study is managed by Temple University Alzheimer’s Center in collaboration with Crozer Keystone Health System. NO drug involved
The study will evaluate longitudinally whether the presence of cardiovascular (CV) risk factors (particularly hypertension and hyperhomocysteinemia), in an age and gender-matched population including cognitive normal, subjects with mild cognitive impairment (MCI) and Alzheimer's disease, contributes to the progression of cognitive decline, and assess whether changes in MRI measures and blood biomarkers associated with neurovascular dysfunction correlate with the cognitive outcome. In addition, the study will evaluate whether the presence of CV risk factors contributes longitudinally to the progression of cognitive decline based on cognitive assessment scores. We will also assess whether blood biomarkers associated with vascular, neuronal and glial/inflammatory changes in the brain, and MRI measures, correlate longitudinally with cognitive scores, psychosocial state, as well as with each other, and whether the presence of CV risk factors contributes to the observed biomarker changes.
Description
We will evaluate longitudinally whether the presence of cardiovascular (CV) risk factors (particularly hypertension, HT and hyperhomocysteinemia, HHcy), in an age and gender-matched population including cognitive normal, subjects with mild cognitive impairment (MCI) and AD, contributes to the progression of cognitive decline, and assess whether changes in MRI measures and blood biomarkers associated with neurovascular dysfunction correlate with the cognitive outcome.
We will recruit and enroll at the Crozer Keystone Center for Geriatric Medicine a cohort of age and gender-matched cognitive normal (NL), MCI and AD individuals. All participants will undergo the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Exam (MMSE), psychosocial tests, a blood draw to collect plasma and serum at recruitment (baseline), as well as after 1 and 2 years, and an MRI scan at year 1 and year 2. Novel and established blood biomarkers of AD and neurovascular dysfunction will be measured at the 3 time points using a state of the art high sensitivity approach (Quanterix Simoa). MRI measures will include gray matter volumes, hippocampal segmentation as well as analysis of white matter abnormalities.
We will evaluate whether the presence of CV risk factors contributes longitudinally to the progression of cognitive decline based on the MoCA and MMSE scores.
We will assess whether blood biomarkers associated with vascular, neuronal and glial/inflammatory changes in the brain, and MRI measures, correlate longitudinally with MoCA and MMSE cognitive scores, psychosocial state, as well as with each other, and whether the presence of CV risk factors contributes to the observed biomarker changes.
Over the normal life span and over time, and in particular in presence of MCI and AD, hippocampal and cortical atrophy rates and plasma biomarkers associated with neurovascular degeneration increase, while memory performance decreases.
We hypothesize that the presence of CV risk factors will contribute to worsening of memory, impaired psychosocial activity, and changes in blood and imaging biomarkers associated with neuronal and vascular dysfunction in elderly cognitively normal, MCI and AD subjects.
This aim will allow us to characterize the contribution of CV risk to the longitudinal rates of cognitive performance, plasma biomarker expression, hippocampal and cortical atrophy, and cerebrovascular imaging complications in elderly and AD.
We propose to examine150 gender-matched individuals between the ages of 60-90 years (50 NL, 50 MCI, 50 AD), of whom about ½ will present CV risk factors (HT and/or HHcy), longitudinally studied over a 2-years period. Each person recruited will be subjected to 3 (baseline, 1 year and 2 years) clinical and psychometric evaluations at least two research-quality MRI scans (baseline and 2 years). Blood draws will be obtained for all these subjects at each examination (0, 1, and 2 years) for clinical lab assessments, as well as to obtain plasma and serum for biomarker analysis.
Details
| Condition | Alzheimer's Disease, Mild Cognitive Impairment |
|---|---|
| Clinical Study Identifier | TX299828 |
| Last Modified on | 9 September 2022 |
How understandable was the trial content above?
Hard to understand
Easy to understand
How to participate?
Step
1
Connect with a study center
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Step
2
Get screened
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn more
Step
3
Enroll in the clinical study
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn more
Step
4
Get your study results
Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer